Medical-device giant Boston Scientific (BSX) was down sharply Wednesday after the U.S. government proposed limiting coverage of its new heart implant. Late Tuesday, the Center for Medicare and Medicaid Service (CMS) issued the proposed guidelines covering the use of percutaneous left atrial appendage closure therapy, which is the purpose of Boston Scientific’s Watchman device. The memo concluded that “the evidence is sufficient to determine
Medical-device maker Boston Scientific (BSX) beat analysts’ Q3 estimates and raised guidance Wednesday, sending the stock up sharply. Boston Scientific made 24 cents a share in the quarter, excluding one-time items, up 20% from the year-earlier quarter and beating analysts’ consensus by a penny, according to Thomson Reuters. Revenue rose 2% to $1.89 billion, some $27 million above Wall Street’s estimate. Excluding the foreign-exchange impact,
Medical-device giant Boston Scientific (BSX) beat analysts’ Q4 profit estimates Tuesday, but shares fell on the stock market today as analysts spotted weaknesses in other aspects of the report. The company said profit rose 17% over the year-earlier quarter to 21 cents a share, beating analysts’ consensus by 8 cents, according to Thomson Reuters. Sales rose 1% to $1.84 billion, slightly ahead of consensus. Boston Sci also offered 2014 guidance for